Amantadine for Parkinson’s Disease

admin
February 23, 2026

This eBook from Blue Heron Health News

Back in the spring of 2008, Christian Goodman put together a group of like-minded people – natural researchers who want to help humanity gain optimum health with the help of cures that nature has provided. He gathered people who already know much about natural medicine and setup blueheronhealthnews.com.

Today, Blue Heron Health News provides a variety of remedies for different kinds of illnesses. All of their remedies are natural and safe, so they can be used by anyone regardless of their health condition. Countless articles and eBooks are available on their website from Christian himself and other natural health enthusiasts, such as Julissa Clay , Shelly Manning , Jodi Knapp and Scott Davis.

The Parkinson’s Protocol By Jodi Knapp Parkinson’s disease cannot be eliminated completely but its symptoms can be reduced, damages can be repaired and its progression can be delayed considerably by using various simple and natural things. In this eBook, a natural program to treat Parkinson’s disease is provided online. it includes 12 easy steps to repair your body and reduce the symptoms of this disease.

Amantadine for Parkinson’s Disease

Parkinson’s disease (PD) is a chronic, progressive neurodegenerative disorder characterized by motor and non-motor symptoms. Its cardinal motor features include tremor, rigidity, bradykinesia, and postural instability, while non-motor symptoms span cognitive decline, depression, sleep disturbances, and autonomic dysfunction. The pathological hallmark is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to impaired basal ganglia function.

Although levodopa remains the most effective symptomatic therapy, additional pharmacological agents play crucial roles in comprehensive management. Among them, amantadine is a unique drug with multiple mechanisms of action, offering both dopaminergic and non-dopaminergic effects. Originally developed as an antiviral agent against influenza A, amantadine was serendipitously discovered to have antiparkinsonian properties in the late 1960s. Since then, it has been utilized in various contexts, including early symptomatic treatment, adjunctive therapy, and management of levodopa-induced dyskinesias (LID).

This essay explores the pharmacology, clinical efficacy, therapeutic uses, limitations, and future perspectives of amantadine in Parkinson’s disease treatment.

Pharmacological Profile

Amantadine is a synthetic tricyclic amine with a well-documented safety profile. Its antiparkinsonian effects arise from a combination of mechanisms:

  1. Dopaminergic modulation – Amantadine enhances dopamine release, inhibits dopamine reuptake, and possibly stimulates dopamine receptors, thereby increasing dopaminergic tone in the striatum.

  2. NMDA receptor antagonism – By blocking N-methyl-D-aspartate (NMDA) glutamate receptors, amantadine reduces excitotoxic glutamatergic transmission. This is particularly relevant in mitigating levodopa-induced dyskinesias.

  3. Anticholinergic-like effects – Although weak, amantadine exerts some indirect anticholinergic actions, contributing modestly to tremor relief.

  4. Neuroprotective potential – Preclinical studies suggest neuroprotective effects via inhibition of glutamate-mediated excitotoxicity and oxidative stress, although clinical confirmation remains limited.

This diverse pharmacological profile distinguishes amantadine from purely dopaminergic agents and underpins its unique clinical utility.

Clinical Efficacy

1. Early Symptomatic Treatment

Amantadine can provide modest symptomatic relief in early Parkinson’s disease, especially before initiation of levodopa. It improves bradykinesia, rigidity, and tremor, although its efficacy is weaker than that of levodopa or dopamine agonists. Its advantages include oral availability, rapid onset of action, and favorable tolerability in younger patients.

However, symptomatic benefit often wanes after several months of use, limiting its role as long-term monotherapy.

2. Adjunctive Therapy with Levodopa

Amantadine is frequently used in combination with levodopa to enhance motor control. It can:

  • Reduce motor fluctuations.

  • Provide additive benefits for rigidity and bradykinesia.

  • Improve tremor in some patients.

Nevertheless, the most significant role of amantadine is in the management of levodopa-induced dyskinesias.

3. Levodopa-Induced Dyskinesias (LID)

Dyskinesias are involuntary, abnormal movements that develop in many patients after chronic levodopa use. They significantly impair quality of life and represent a major therapeutic challenge. Amantadine is the only widely accepted pharmacological treatment with proven efficacy against LID.

  • Mechanism: NMDA receptor antagonism reduces glutamatergic hyperactivity implicated in dyskinesia pathogenesis.

  • Evidence: Multiple randomized controlled trials demonstrate a reduction in dyskinesia severity with amantadine, both immediate-release (IR) and extended-release (ER) formulations.

  • Extended-release formulations such as Gocovri® have been developed to optimize plasma levels, showing improved efficacy and tolerability compared with conventional IR dosing.

Thus, amantadine occupies a unique and irreplaceable role in controlling dyskinesias.

Formulations and Dosing

  • Immediate-release (IR) amantadine: Typically administered at 100–300 mg/day, divided into two or three doses.

  • Extended-release (ER) amantadine: Provides sustained drug levels, improving dyskinesia control and minimizing nocturnal symptoms. Common ER doses are 274 mg once daily at bedtime.

Dosing adjustments are essential in patients with renal impairment, as amantadine is excreted primarily by the kidneys.

Adverse Effects

Although generally well tolerated, amantadine is associated with dose-related side effects.

Common adverse effects:

  • Livedo reticularis (a mottled, purplish skin discoloration).

  • Peripheral edema.

  • Dry mouth.

  • Constipation.

  • Insomnia.

  • Orthostatic hypotension.

Central nervous system effects:

  • Confusion.

  • Hallucinations.

  • Agitation.

  • Impaired concentration.

These CNS adverse effects are more common in elderly patients or those with pre-existing cognitive impairment, limiting amantadine’s use in advanced PD with dementia.

Rare but serious adverse effects:

  • Psychosis.

  • Seizures (at high doses).

  • Cardiac arrhythmias.

Contraindications and Precautions

Amantadine should be avoided or used cautiously in:

  • Elderly patients with dementia or psychosis – risk of hallucinations and confusion.

  • Renal impairment – requires dose adjustment.

  • Epilepsy – may lower seizure threshold.

  • Congestive heart failure – risk of peripheral edema.

  • Angle-closure glaucoma – exacerbation due to mild anticholinergic effects.

Comparative Role in Parkinson’s Therapy

In the modern treatment landscape, amantadine holds a distinct role compared with other PD therapies:

  • Levodopa: Remains the most effective for motor symptom control, but amantadine adds value by addressing dyskinesias.

  • Dopamine agonists and MAO-B inhibitors: Often used as early adjunctive therapies; amantadine provides a unique glutamatergic mechanism not shared by these drugs.

  • Anticholinergics: Both reduce tremor, but amantadine is generally better tolerated and provides broader symptomatic relief.

Thus, amantadine complements rather than replaces dopaminergic therapies.

Evidence from Clinical Studies

Several key clinical trials highlight amantadine’s role:

  • Early symptomatic trials (1970s–1980s): Demonstrated mild to moderate improvement in parkinsonian symptoms compared to placebo.

  • Dyskinesia trials: Randomized controlled studies show significant reduction in LID severity with both IR and ER amantadine.

  • Gocovri studies: Extended-release formulation provided up to 40–50% reduction in dyskinesia scores, with additional benefit on “off†time reduction.

Systematic reviews and meta-analyses confirm its unique efficacy in dyskinesia, though symptomatic effects on core PD features are modest.

Limitations of Amantadine

Despite its benefits, several limitations restrict its widespread use:

  1. Tachyphylaxis – Symptomatic benefit for motor symptoms often diminishes after months of therapy.

  2. Adverse effects – Particularly CNS-related, limiting its use in older populations.

  3. Lack of disease modification – No proven neuroprotective effect in clinical settings, despite preclinical promise.

  4. Variable individual response – Some patients report substantial benefits, while others experience minimal improvement.

Future Directions

Research into amantadine continues in several areas:

  1. Improved formulations – Extended-release amantadine has already enhanced therapeutic potential, but further optimization of delivery systems is ongoing.

  2. Neuroprotective trials – Studies are investigating whether early amantadine use may confer long-term disease-modifying benefits, though results remain inconclusive.

  3. Combination therapy – Exploration of synergistic effects with other glutamatergic modulators or dopaminergic drugs may expand therapeutic options.

  4. Biomarker-driven therapy – Identifying patient subgroups most likely to benefit from amantadine could improve individualized treatment.

Conclusion

Amantadine is a unique pharmacological agent in the treatment of Parkinson’s disease, distinguished by its dual dopaminergic and antiglutamatergic mechanisms. Although its role as an early symptomatic agent has diminished with the availability of more effective therapies, it remains valuable as an adjunct to levodopa. Most importantly, it is the only pharmacological treatment with established efficacy in reducing levodopa-induced dyskinesias, making it indispensable in modern PD management.

Its use, however, is limited by side effects, especially in elderly or cognitively impaired patients, and by the waning of symptomatic benefit over time. Extended-release formulations have addressed some of these limitations and improved therapeutic outcomes.

In conclusion, while amantadine is not a first-line treatment for core motor symptoms, it holds a crucial role in comprehensive Parkinson’s disease management. Its unique pharmacological profile ensures continued relevance, particularly for patients suffering from dyskinesias, where alternative pharmacological options are lacking. Future research may further refine its utility, optimize tolerability, and possibly expand its role beyond symptomatic relief.

The Parkinson’s Protocol By Jodi Knapp Parkinson’s disease cannot be eliminated completely but its symptoms can be reduced, damages can be repaired and its progression can be delayed considerably by using various simple and natural things. In this eBook, a natural program to treat Parkinson’s disease is provided online. it includes 12 easy steps to repair your body and reduce the symptoms of this disease.

This eBook from Blue Heron Health News

Back in the spring of 2008, Christian Goodman put together a group of like-minded people – natural researchers who want to help humanity gain optimum health with the help of cures that nature has provided. He gathered people who already know much about natural medicine and setup blueheronhealthnews.com.

Today, Blue Heron Health News provides a variety of remedies for different kinds of illnesses. All of their remedies are natural and safe, so they can be used by anyone regardless of their health condition. Countless articles and eBooks are available on their website from Christian himself and other natural health enthusiasts, such as Julissa Clay , Shelly Manning , Jodi Knapp and Scott Davis.
Mr.Hotsia

I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way.I share my experiences on www.hotsia.com